$5.7 billion. That’s the amount the Department of Justice recovered in healthcare-related False Claims Act settlements and judgments in fiscal year 2026, a figure that underscores the escalating regulatory scrutiny facing the industry – and a trend poised to intensify with the formation of a new Health Care Task Force at the Federal Trade Commission. While the FTC, under Chairman Andrew Ferguson, has historically focused on competition, the March 20, 2026, memorandum establishing this task force signals a broadening scope, one that directly follows the money trail of healthcare costs and consumer protection. This isn’t simply about adding another layer of bureaucracy; it’s a strategic realignment reflecting the Trump Administration’s stated priorities, outlined in Executive Order 14211 and the “Great Healthcare Plan,” to drive down costs and increase transparency.
Follow the money, and you’ll see the FTC’s priorities taking shape. The Task Force, drawing personnel from the Bureaus of Competition, Consumer Protection, and Economics, isn’t tasked with creating new regulations, as Ferguson explicitly states that “anticompetitive regulations further undermine incentives to lower costs.” Instead, the focus is on enforcement – leveraging existing laws to challenge practices the FTC deems unfair or deceptive. This is a crucial distinction. While legislative changes often face protracted battles, enforcement actions can yield immediate results, impacting bottom lines and reshaping industry behavior. The $5.7 billion recovered by the DOJ demonstrates the financial impact of this approach, and the FTC appears intent on mirroring that success.
See the original crowell.com story for the full account.
The memo’s thematic hints point to three key areas of investigation. First, pharmacy benefit managers (PBMs) are firmly in the crosshairs. The FTC is actively challenging PBM practices that obscure pricing, inflate costs for consumers, and potentially harm independent pharmacies. This isn’t a new battle – the National Community Pharmacists Association has long argued PBMs wield undue market power – but the FTC’s involvement elevates the stakes. Second, the agency is signaling a willingness to block mergers and challenge patent listings to preserve competition in the pharmaceutical and medical device sectors. In 2025, healthcare mergers totaled $68.2 billion, a 15% increase year-over-year, indicating a consolidation trend the FTC is now actively resisting. Finally, deceptive marketing practices, particularly those targeting vulnerable populations, are drawing increased scrutiny. The FTC’s recent actions against misleading advertising for weight-loss programs and unsubstantiated health claims demonstrate this commitment.
The creation of the Health Care Task Force isn’t happening in a vacuum. Ferguson intends for the group to collaborate with the Department of Justice and the Department of Health and Human Services, agencies already aggressively policing the healthcare sector. The DOJ’s $5.7 billion recovery, representing 83.8% of all False Claims Act recoveries in fiscal year 2026, highlights the scale of existing enforcement efforts. This interagency coordination suggests a unified front, maximizing the impact of regulatory oversight. The memo specifically mentions “knowledge-sharing” and “targeted enforcement initiatives,” indicating a deliberate effort to avoid duplication and streamline investigations. This coordinated approach is a departure from previous administrations, where agencies sometimes operated in silos, diminishing overall effectiveness.
What this means for your wallet: expect increased scrutiny of healthcare pricing and marketing. Consumers should be wary of health-related products and services with exaggerated claims, and businesses should proactively review their compliance programs to ensure transparency and avoid deceptive practices. The key question now is whether the FTC’s enforcement actions will translate into tangible cost savings for consumers, or simply shift the burden of compliance onto healthcare providers. Investors should closely monitor companies operating in the PBM, pharmaceutical, and medical device sectors, as increased regulatory pressure could significantly impact their financial performance. Specifically, watch for any FTC challenges to proposed mergers or patent filings – these actions will be a clear indicator of the Task Force’s priorities and its willingness to disrupt the status quo.
